BIOGEN INC.
About BIOGEN INC.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $9.9B
- Net income
- $1.3B
- Total assets
- $29.4B
- Market cap
- $28.8B
- Gross margin
- 75.7%
- Operating margin
- 15.7%
- Net margin
- 13.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.9B
- Cost of revenue
- $2.4B
- Gross profit
- $7.5B
- Operating expenses
- $5.9B
- Operating income
- $1.6B
- Income tax
- $263.6M
- Net income
- $1.3B
- EPS (basic)
- $8.83
- EPS (diluted)
- $8.79
Balance sheet
- Total assets
- $29.4B
- Current assets
- $9.0B
- Total liabilities
- $11.2B
- Current liabilities
- $3.3B
- Shareholders’ equity
- $18.3B
Cash flow
- Operating cash flow
- $2.2B
- Investing cash flow
- -$1.4B
- Financing cash flow
- -$301.9M
- Net cash flow
- $633.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $28.8B
- P/E ratio
- 21.9
- EPS (diluted)
- $8.79
- Shares outstanding
- 149.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 17, 1991
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.3B in FY2025.
- Revenue declined 26% from FY2020 to FY2025.
- Gross margin of 75.7%, net margin 13.1%.
- Trading 6% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 21.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIOGEN INC..
Write a review
News about BIOGEN INC.
News & sentiment via Polygon.io
